Biotricity, Inc., medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated electrocardiogram (ECG) device and software solution. The company is based in Redwood City, California.
IPO Year:
Exchange: NASDAQ
Website: biotricity.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | Buy → Neutral | H.C. Wainwright | |
| 3/7/2022 | $5.00 | Buy | Lake Street |
| 11/23/2021 | $6.00 | Buy | HC Wainwright & Co. |
REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev
Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p
Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn
Company expects to report Q3-FY25 revenue growth of 22% from the corresponding prior year quarter to $3.6 million – an 11% increase sequentially from the immediately preceding quarterManagement continues to drive recurring revenue growth and efficienciesCompany to report positive cash flow for Q3-FY25 on current operating basis, before interest, dividends and amortizationCompany to report improved gross margins and operating results, as the Company nears its goal of achieving profitabilityManagement to release full financial results on Wednesday February 19th and host its Q3 Fiscal Year 2025 Financial Results Call on Thursday February 20th at 5:30 PM EST. REDWOOD CITY, Calif., Feb. 17, 202
REDWOOD CITY, Calif. and BELFAST, Northern Ireland, Jan. 15, 2025 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY), a provider of remote cardiac monitoring solutions, and B-Secur, a leader in biosensing technology, have joined forces to create one of the most advanced, device-neutral platforms for integrated heart monitoring. By combining B-Secur's HeartKey® technology, a suite of FDA-cleared algorithms and analytics, with Biotricity's medical and consumer diagnostic solutions, the new partnership will empower Integrated Delivery Networks, healthcare providers, health systems, and
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without any need for future financing. REDWOOD CITY, Calif., Dec. 27, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced that it has completed a series of financings that bolster the Company's financial health, reduce execution risk, and provide it with the necessary resources to achieve profitability. Company has all the
First Time in the Company's History REDWOOD CITY, Calif., Dec. 3, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced achieving positive free cash flow, a measure of financial health and another major milestone towards profitability. Dr. Waqaas Al-Siddiq, Biotricity's Founder & CEO, explains: "While continuing on our mission to produce transformative healthcare technologies, we have demonstrated a strong commitment to growth and operational efficiency through innovation, automation and financial discipline, driving revenue and margins
Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improveCompany reports Q2-FY25 revenue grew by 13% YOY to $3.3 millionGross margins continued to meet management expectations for improvement at 75.3%, a significant improvement from 69.1% for the same period last yearRecurring Technology Fee revenue comprised 94% of total revenue with a 79% gross profit percentageRecurring technology fees, additional device sales to existing customers see continued growthReduced SG&A to $2.25 million from $3.5 million, down 35.5% compared to the same period last yearNet loss attri
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 15, 2024. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will de
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
3 - BIOTRICITY INC. (0001630113) (Issuer)
3 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
H.C. Wainwright downgraded Biotricity from Buy to Neutral
Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00
HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00
10-Q/A - BIOTRICITY INC. (0001630113) (Filer)
10-Q - BIOTRICITY INC. (0001630113) (Filer)
NT 10-Q - BIOTRICITY INC. (0001630113) (Filer)
8-K - BIOTRICITY INC. (0001630113) (Filer)
10-Q - BIOTRICITY INC. (0001630113) (Filer)
25-NSE - BIOTRICITY INC. (0001630113) (Subject)
10-Q - BIOTRICITY INC. (0001630113) (Filer)
8-K - BIOTRICITY INC. (0001630113) (Filer)
NT 10-Q - BIOTRICITY INC. (0001630113) (Filer)
8-K - BIOTRICITY INC. (0001630113) (Filer)
SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)
SC 13G - BIOTRICITY INC. (0001630113) (Subject)
REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev
Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p
Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn
Company expects to report Q3-FY25 revenue growth of 22% from the corresponding prior year quarter to $3.6 million – an 11% increase sequentially from the immediately preceding quarterManagement continues to drive recurring revenue growth and efficienciesCompany to report positive cash flow for Q3-FY25 on current operating basis, before interest, dividends and amortizationCompany to report improved gross margins and operating results, as the Company nears its goal of achieving profitabilityManagement to release full financial results on Wednesday February 19th and host its Q3 Fiscal Year 2025 Financial Results Call on Thursday February 20th at 5:30 PM EST. REDWOOD CITY, Calif., Feb. 17, 202
REDWOOD CITY, Calif. and BELFAST, Northern Ireland, Jan. 15, 2025 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY), a provider of remote cardiac monitoring solutions, and B-Secur, a leader in biosensing technology, have joined forces to create one of the most advanced, device-neutral platforms for integrated heart monitoring. By combining B-Secur's HeartKey® technology, a suite of FDA-cleared algorithms and analytics, with Biotricity's medical and consumer diagnostic solutions, the new partnership will empower Integrated Delivery Networks, healthcare providers, health systems, and
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without any need for future financing. REDWOOD CITY, Calif., Dec. 27, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced that it has completed a series of financings that bolster the Company's financial health, reduce execution risk, and provide it with the necessary resources to achieve profitability. Company has all the
First Time in the Company's History REDWOOD CITY, Calif., Dec. 3, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced achieving positive free cash flow, a measure of financial health and another major milestone towards profitability. Dr. Waqaas Al-Siddiq, Biotricity's Founder & CEO, explains: "While continuing on our mission to produce transformative healthcare technologies, we have demonstrated a strong commitment to growth and operational efficiency through innovation, automation and financial discipline, driving revenue and margins
Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improveCompany reports Q2-FY25 revenue grew by 13% YOY to $3.3 millionGross margins continued to meet management expectations for improvement at 75.3%, a significant improvement from 69.1% for the same period last yearRecurring Technology Fee revenue comprised 94% of total revenue with a 79% gross profit percentageRecurring technology fees, additional device sales to existing customers see continued growthReduced SG&A to $2.25 million from $3.5 million, down 35.5% compared to the same period last yearNet loss attri
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 15, 2024. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will de
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results